Short description
CorMedix is a specialty pharmaceutical company that develops products for the treatment of cardiac, renal and infectious diseases.
Description
CorMedix Inc. is a specialty pharmaceutical company that develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Specifically, our goal is to treat human disease by reducing commonly associated renal, cardiovascular, metabolic and infectious complications. Our therapeutic candidates may be small molecules, biologics, chemical entities, devices and/or diagnostics (molecular/lab tests) that enable targeted therapy in these areas.
CorMedix has received CE Mark approval for Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients. Our goal is to provide risk mitigation solutions for central venous catheters (CVCs) in a variety of important indications.
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Bridgewater, New Jersey, United States, North America
Founded on
January 1, 2006
Exited on
January 21, 2021
Went public on
January 21, 2021
Stock symbol
CRMD
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Founders
Antony Pfaffle